New Products In Brief
This article was originally published in The Gray Sheet
Executive SummaryRight side of heart pump: FDA grants Humanitarian Device Exemption on Oct. 7 to Levitronix' CentriMag right ventricular assist system for temporary support of critically ill patients with a failing right ventricle. Safety data from two multi-center clinical trials showed that the benefits of CentriMag outweigh its risks, FDA says. The device is designed to support patients up to 14 days or until a heart transplant or long-term heart assist device can be implanted. "While severe right-side heart failure is uncommon, it can lead to death," states FDA. "It is often caused by left-side heart failure or, in unusual cases, by heart surgery.
You may also be interested in...
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced October to November.